Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2026 16:05 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
April 17, 2026 16:05 ET | Source: SEALSQ

SEALSQ Announces Agenda of its 2026 Annual General Meeting of Shareholders

Geneva, Switzerland, April 17, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (“SEALSQ” or “the Company”) (NASDAQ: LAES), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum...
April 17, 2026 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and...
April 17, 2026 16:05 ET | Source: Vera Bradley, Inc.

Vera Bradley Terminates Existing Shareholder Rights Plan

Vera Bradley Terminates Existing Shareholder Rights Plan
April 17, 2026 16:05 ET | Source: ALX Oncology

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel...
April 17, 2026 16:03 ET | Source: Value Line, Inc.

VALUE LINE, INC. DIVIDEND HAS JUST BEEN RAISED FROM $1.30 TO $1.40 (ANNUALIZED) – ITS 12TH CONSECUTIVE INCREASE

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Value Line, Inc. (NASDAQ – VALU) announced today that its Board of Directors has just raised its quarterly dividend, which will be $0.35 per common...
April 17, 2026 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...
April 17, 2026 16:01 ET | Source: New Era Energy & Digital, Inc.

New Era Energy & Digital Announces Appointment of Andy Casazza as Chief Corporate Officer

MIDLAND, Texas, April 17, 2026 (GLOBE NEWSWIRE) -- New Era Energy & Digital, Inc. (Nasdaq: NUAI) (“New Era” or the “Company”), a developer and operator of next-generation digital infrastructure...
April 17, 2026 16:01 ET | Source: Adagene Inc.

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively...
April 17, 2026 16:01 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models Consistent with Xilio’s clinically-validated masking technology,...